ABSI

Absci Corp

ABSI, USA

Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to design differentiated antibody therapeutics. Its preclinical development programs include ABS-101 for the treatment of inflammatory bowel disease; ABS-201 for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology. Absci Corporation has collaboration agreements with PrecisionLife, Memorial Sloan Kettering Cancer Center, Twist Bioscience, Owkin, Oracle Corporation, and Advanced Micro Devices, Inc. for joint research and development activities. The company was founded in 2011 and is headquartered in Vancouver, Washington.

https://www.absci.com

Stock Price

$0.00

0%

increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
ABSI
stock
ABSI

Absci Corporation's (NASDAQ:ABSI) recent 12% pullback adds to one-year year losses, institutional owners may take drastic measures Yahoo Finance

Read more →
ABSI
stock
ABSI

Absci Showcases Generative AI Drug Platform and Pipeline TipRanks

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

STRONG BUY

Target Price:

$8.0457

Analyst Picks

Strong Buy

5

Buy

4

Hold

0

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Medium

1.98

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-13.65 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-11.72 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

-6,876.46 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Very High

0.16

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 96.55% of the total shares of Absci Corp

1.

FMR Inc

(12.7966%)

since

2025/06/30

2.

ARK Genomic Revolution ETF

(7.7842%)

since

2025/08/28

3.

ARK Investment Management LLC

(6.7187%)

since

2025/06/30

4.

ARK Genomic Revolution

(6.3366%)

since

2025/06/30

5.

Fidelity Growth Compy Commingled Pl S

(6.1891%)

since

2025/07/31

6.

BlackRock Inc

(5.5915%)

since

2025/06/30

7.

Redmile Group, LLC

(5.5198%)

since

2025/06/30

8.

Fidelity Growth Company Fund

(4.3445%)

since

2025/07/31

9.

Vanguard Group Inc

(4.3148%)

since

2025/06/30

10.

Vanguard Total Stock Mkt Idx Inv

(2.7288%)

since

2025/07/31

11.

Fred Alger Management, LLC

(2.6279%)

since

2025/06/30

12.

Woodline Partners LP

(1.9837%)

since

2025/06/30

13.

iShares Russell 2000 ETF

(1.7445%)

since

2025/08/31

14.

Columbia Acorn Inst

(1.7167%)

since

2025/07/31

15.

Ameriprise Financial Inc

(1.7158%)

since

2025/06/30

16.

Alger Small Cap Focus I

(1.6512%)

since

2025/06/30

17.

Alger Small Cap Focus Composite

(1.6512%)

since

2025/06/30

18.

Geode Capital Management, LLC

(1.6355%)

since

2025/06/30

19.

Fidelity Growth Company K6

(1.4911%)

since

2025/07/31

20.

Massachusetts Financial Services Company

(1.4895%)

since

2025/06/30

21.

UBS Group AG

(1.2766%)

since

2025/06/30

22.

Bank of America Corp

(1.2491%)

since

2025/06/30

23.

Fidelity Series Growth Company

(1.2263%)

since

2025/07/31

24.

State Street Corp

(1.2059%)

since

2025/06/30

25.

Fidelity Select Biotechnology

(1.1939%)

since

2025/07/31

26.

Royce & Associates, LP

(1.0158%)

since

2025/06/30

27.

MFS New Discovery I

(1.0013%)

since

2025/07/31

28.

Sumitomo Mitsui Trust Group Inc

(0.9776%)

since

2025/06/30

29.

Amova Asset Management Americas, Inc

(0.9681%)

since

2025/06/30

30.

Morgan Stanley - Brokerage Accounts

(0.8355%)

since

2025/06/30

31.

Fidelity Small Cap Index

(0.7319%)

since

2025/06/30

32.

Vanguard Institutional Extnd Mkt Idx Tr

(0.6939%)

since

2025/07/31

33.

Casdin Capital, LLC

(0.6509%)

since

2025/06/30

34.

Royce Micro Cap Trust

(0.6133%)

since

2025/06/30

35.

Dimensional Fund Advisors, Inc.

(0.5612%)

since

2025/06/30

36.

Charles Schwab Investment Management Inc

(0.5502%)

since

2025/06/30

37.

iShares Russell 2000 Growth ETF

(0.5318%)

since

2025/08/31

38.

Alger Small Cap Growth B

(0.4446%)

since

2025/06/30

39.

iShares Biotechnology ETF

(0.4403%)

since

2025/08/31

40.

Vanguard Russell 2000 ETF

(0.3492%)

since

2025/07/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

-0.18

Latest Release

Date

2025-09-30

EPS Actual

-0.2

EPS Estimate

-0.2

EPS Difference

0

Surprise Percent

0%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Weak Deep Value(3)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(4.8)
GARP
Not Attractive for GARP(2.5)
Growth
Weak Growth Prospect(1)
Momentum
Moderate Momentum(3.5)
Net Net
Not Undervalued (Net-Net)(1)
Quality
Low Quality Business(2.5)
Value
Fair Value(4.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.